TIBCS 2023


Time (UTC+8) Topic Speaker Moderator Abstract Slides Live streaming
08:00 - 08:20 Registration
08:20 - 08:30 Opening Remark
Shou-Tung Chen
08:30 - 08:40 [Young Investigator Presentation] Investigating the Connection Between LSM1 and Energy Metabolism in Breast Cancer through Spatial Transcriptome and Single-Cell RNA Sequencing
Yen-Dun Tony Tzeng
Chen-Hsiang Chang
08:40 - 08:50 [Young Investigator Presentation] Unveiling the Molecular Mechanism of Endocrine Resistance: Insights from Epigenetic Reprogramming and Coupled Transcription Factors in Estrogen Receptor Positive Breast Cancer
An-Chieh Feng
Chen-Hsiang Chang
08:50 - 09:00 [Young Investigator Presentation] Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study
Han-Fang Cheng
Chen-Hsiang Chang
09:00 - 09:30 Immune Checkpoint Inhibitor in Neoadjuvant or Adjuvant Setting for Breast Cancer: the Paradigm Shift
Sibylle Loibl
Yuan-Ching Chang
09:30 - 10:00 Management of ER+ HER2- mBC: Bringing Together Clinical & Real-World Evidence
Adam M. Brufsky
Dar-Ren Chen
10:00 - 10:30 Coffee Break
10:30 - 11:00 Management of Older Patients with Breast Cancer
Etienne Brain
King-Jen Chang
11:00 - 11:15 Management of Ipsilateral Local Recurrence: Surgical View
Han-Byoel Lee
Chao-Ming Hung
11:15 - 11:30 Management of Ipsilateral Local Recurrence: Radiation Oncology View
Chin-Nan Chu
Huan-Ming Hsu
11:30 - 11:55 Supraclavicular axillary disease management
Shih-Che Shen
Wen-Hung Kuo
11:55 - 12:10 Contralateral axillary disease management
Soong June Bae
Frank Fu Ou-Yang
12:10 - 12:30 Panel Discussion
Byung Joo Chae
Jun Won Min
Kuo-Ting Lee
Chiao Lo
Chin-Yao Lin
12:30 - 13:10 [Luncheon Symposium] Interpret the Role of GnRH Agonist from Clinical Trial into Local Practice in Early Breast Cancer
Ming-Yang Wang
Yao-Jen Chang
13:00 - 13:30 Break
13:30 - 14:00 Reducing the Risk of Recurrence in HR+, HER2- High-Risk Early Breast Cancer
Hiroko Masuda
Ling-Ming Tseng
14:00 - 14:30 Gene Assay tools to Inform Chemotherapy Benefit in HR+ HER2- Anatomically High Risk Early Breast Cancer
Kevin Kalinsky
Cheng-Ping Yu
14:30 - 15:00 Exploring the Potential of Ribociclib and Endocrine Therapy in Early Breast Cancer: Findings from the NATALEE Trial
Stephen Chia
Chiun-Sheng Huang
15:00 - 15:30 Panel Discussion: Adjuvant treatment for HR+ HER2-EBC, more or less
Hiroko Masuda
Kevin Kalinsky
Stephen Chia
Chin-Sheng Hung
Jiun-I Lai
Chun-Yu Liu
15:30 - 15:50 Coffee Break
15:50 - 16:20 Current Treatment Strategies for High-Risk Patients with HER2+ Early-Stage Breast Cancer: Can We Improve Clinical Outcomes
Miguel Martin
Shin-Cheh Chen
16:20 - 16:50 Current Challenges in Treating Patients with HER2 positive Breast Cancer: Leave no Options Behind
Nadia Harbeck
Fang-Ming Chen
16:50 - 17:20 Shape the Treatment Paradigm of HER2-low MBC: From Guideline to Clinical Practice
Giuseppe Curigliano
Tsu-Yi Chao
17:20 - 17:50 Promising New Drugs Development for MBC
Peter Schmid
Ming-Feng Hou
Time (UTC+8) Topic Speaker Moderator Abstract Slides Live streaming
08:00 - 08:10 Registration
08:10 - 08:20 [Oral Presentation]GRK6 recruits the β-Arrestin 2/MAPK/NF-κB signaling axis for promoting the metastatic progression of triple-negative breast cancer
Wen-Ke Wang
Chi-Cheng Huang
08:20 - 08:40 [Oral Presentation]A competing risk analysis study of prognosis in patients with HER2-low and HER2-zero breast cancer
Joseph Lin
Chi-Cheng Huang
08:40 - 08:50 [Oral Presentation]Exploration of Cuproptosis-Related Hub Genes and Microenvironmental Landscape in Breast Cancer using Integrated Spatial Transcriptome and Single-Cell RNA-Sequencing
Jui-Hu Hsiao
Chi-Cheng Huang
08:50 - 09:20 What Can We Expect More from Ribociclib in Treating HR+HER2-mBC Patients?
Dwan-Ying Chang
Fiona Tsui-Fen Cheng
09:20 - 09:50 Identification and Characterization of a Proliferative Cell Population in Estrogen Receptor-Positive Metastatic Breast Cancer through Spatial and Single-Cell Transcriptomics
Shiuan Chen
Yen-Shen Lu
09:50 - 10:35 Novel Approaches in Triple Negative and HR+/HER2- Metastatic Breast Cancer - Anti-Trop2 ADC and Future Development
Amy K. Krie
Hsien-Kun Chang
10:35 - 10:50 Award Ceremony &Coffee Break
10:50 - 11:20 Progress of Biomarker Development for Breast Cancer
Aleix Prat
Jyh-Cherng Yu
11:20 - 11:50 Local Regional Management for Patients after Neoadjuvant Therapy
Mehra Golshan
Shyr-Ming Sheen-Chen
11:50 - 12:25 Managing ER-Positive, HER2-Negative Advanced Breast Cancer, A Long Journey
Junichiro Watanabe
Kun-Ming Rau
12:25 - 12:45 Early Breast Cancer Therapy Advancements: Pegylated Liposomal Doxorubicin as a Viable Option
Chung-Liang Li
Guo-Shiou Liao
12:45 - 13:10 [Luncheon Symposium] Refining the Role of Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia
Ming-Shen Dai
Ta-Chung Chao
13:10 - 13:40 Does the Sequence of Anthracycline and Taxane Matter in Chemotherapy of Early Breast Cancer?
Hsu-Huan Chou
Liang-Chih Liu
13:40 - 14:10 Filling the Gap after CDK4/6 Inhibitor: The Evolving Treatment Landscape of Patients with HR+/HER2- mBC
Ching-Hung Lin
Hsien-Tang Yeh
14:10 - 14:40 Break
14:40 - 15:10 Bone Health and Orthopedic Risk Management in Breast Cancer Patients
Po-Hsiang Huang
Yao-Lung Kuo
15:10 - 15:40 Current Experience and Future Perspective in Conducting Biosimilar Clinical Trials in Taiwan
Chiun-Sheng Huang
Shou-Tung Chen
15:40 - 16:10 How to Sequence Treatment therapies in HR+ and LN+EBC
Yi-Fang Tsai
Shen-Liang Shih
16:10 - 16:40 Do We need MRI Study Before and After Neoadjuvant Chemotherapy?
Si-Wa Chan
Chih-Chiang Hung
16:40 - 17:00 Closing
Shou-Tung Chen